Search tips
Search criteria 


Logo of jnnpsycJournal of Neurology, Neurosurgery and PsychiatryVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
J Neurol Neurosurg Psychiatry. 2005 July; 76(7): 934–939.
PMCID: PMC1739697

Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study


Objective: To study the safety and efficacy of a cholinesterase inhibitor, donepezil hydrochloride, for the treatment of dementia in Parkinson's disease (PD).

Methods: This was a randomised double blind, placebo controlled, crossover study in 22 subjects with PD and dementia. Participants were randomised to receive either donepezil followed by identical placebo, or placebo followed by donepezil. Donepezil was administered at 5–10 mg/day. Treatment periods were 10 weeks with a washout period of 6 weeks between the two periods. The primary outcome measure was the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAScog).

Results: Donepezil was well tolerated and most adverse events were mild. There was no worsening of PD symptoms as measured by the total or motor sections of the Unified Parkinson's Disease Rating Scale.

There was a 1.9 point trend toward better scores on the ADAScog on treatment compared with placebo that was not statistically significant. The secondary cognitive measures showed a statistically significant 2 point benefit on the Mini Mental Status Examination and no change on the Mattis Dementia Rating Scale (MDRS). The Clinical Global Impression of Change (CGI) showed a significant 0.37 point improvement on donepezil. No improvement was observed on the MDRS or the Brief Psychiatric Rating Scale. Carryover between treatment periods was observed but was not statistically significant.

Conclusions: Donepezil was well tolerated and did not worsen PD. There may be a modest benefit on aspects of cognitive function. The possible clinical benefit measured by CGI was reflected in only one of the cognitive scales used in this study.

Full Text

The Full Text of this article is available as a PDF (85K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Van Den Eeden Stephen K, Tanner Caroline M, Bernstein Allan L, Fross Robin D, Leimpeter Amethyst, Bloch Daniel A, Nelson Lorene M. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003 Jun 1;157(11):1015–1022. [PubMed]
  • Litvan Irene, Bhatia Kailash P, Burn David J, Goetz Christopher G, Lang Anthony E, McKeith Ian, Quinn Niall, Sethi Kapil D, Shults Cliff, Wenning Gregor K, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord. 2003 May;18(5):467–486. [PubMed]
  • Levy Gilberto, Schupf Nicole, Tang Ming-Xin, Cote Lucien J, Louis Elan D, Mejia Helen, Stern Yaakov, Marder Karen. Combined effect of age and severity on the risk of dementia in Parkinson's disease. Ann Neurol. 2002 Jun;51(6):722–729. [PubMed]
  • Hobson Peter, Meara Jolyon. Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. Mov Disord. 2004 Sep;19(9):1043–1049. [PubMed]
  • Levy G, Tang M-X, Louis ED, Côté LJ, Alfaro B, Mejia H, Stern Y, Marder K. The association of incident dementia with mortality in PD. Neurology. 2002 Dec 10;59(11):1708–1713. [PubMed]
  • Louis ED, Marder K, Cote L, Tang M, Mayeux R. Mortality from Parkinson disease. Arch Neurol. 1997 Mar;54(3):260–264. [PubMed]
  • McKeith IG, Mosimann UP. Dementia with Lewy bodies and Parkinson's disease. Parkinsonism Relat Disord. 2004 May;10 (Suppl 1):S15–S18. [PubMed]
  • Hurtig HI, Trojanowski JQ, Galvin J, Ewbank D, Schmidt ML, Lee VM, Clark CM, Glosser G, Stern MB, Gollomp SM, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology. 2000 May 23;54(10):1916–1921. [PubMed]
  • Perry EK, Curtis M, Dick DJ, Candy JM, Atack JR, Bloxham CA, Blessed G, Fairbairn A, Tomlinson BE, Perry RH. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1985 May;48(5):413–421. [PMC free article] [PubMed]
  • Ruberg M, Ploska A, Javoy-Agid F, Agid Y. Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia. Brain Res. 1982 Jan 28;232(1):129–139. [PubMed]
  • Shinotoh H, Namba H, Yamaguchi M, Fukushi K, Nagatsuka S, Iyo M, Asahina M, Hattori T, Tanada S, Irie T. In vivo mapping of brain cholinergic function in Parkinson's disease and progressive supranuclear palsy. Adv Neurol. 2001;86:249–255. [PubMed]
  • Candy JM, Perry RH, Perry EK, Irving D, Blessed G, Fairbairn AF, Tomlinson BE. Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases. J Neurol Sci. 1983 May;59(2):277–289. [PubMed]
  • Rogers JD, Brogan D, Mirra SS. The nucleus basalis of Meynert in neurological disease: a quantitative morphological study. Ann Neurol. 1985 Feb;17(2):163–170. [PubMed]
  • Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. Dementia. 1996 Nov-Dec;7(6):293–303. [PubMed]
  • Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med. 1998 May 11;158(9):1021–1031. [PubMed]
  • Wilkinson DG. The pharmacology of donepezil: a new treatment of Alzheimer's disease. Expert Opin Pharmacother. 1999 Nov;1(1):121–135. [PubMed]
  • Richard Irene Hegeman, Justus Anne Wallace, Greig Nigel H, Marshall Frederick, Kurlan Roger. Worsening of motor function and mood in a patient with Parkinson's disease after pharmacologic challenge with oral rivastigmine. Clin Neuropharmacol. 2002 Nov-Dec;25(6):296–299. [PubMed]
  • Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry. 2002 Jun;72(6):708–712. [PMC free article] [PubMed]
  • Leroi Iracema, Brandt Jason, Reich Stephen G, Lyketsos Constantine G, Grill Stephen, Thompson Richard, Marsh Laura. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry. 2004 Jan;19(1):1–8. [PubMed]
  • Mohs RC, Cohen L. Alzheimer's Disease Assessment Scale (ADAS). Psychopharmacol Bull. 1988;24(4):627–628. [PubMed]
  • Zec RF, Landreth ES, Vicari SK, Feldman E, Belman J, Andrise A, Robbs R, Kumar V, Becker R. Alzheimer disease assessment scale: useful for both early detection and staging of dementia of the Alzheimer type. Alzheimer Dis Assoc Disord. 1992 Summer;6(2):89–102. [PubMed]
  • Paolo AM, Tröster AI, Glatt SL, Hubble JP, Koller WC. Differentiation of the dementias of Alzheimer's and Parkinson's disease with the dementia rating scale. J Geriatr Psychiatry Neurol. 1995 Jul;8(3):184–188. [PubMed]
  • Juncos Jorge L, Roberts Vicki J, Evatt Marian L, Jewart Rita D, Wood Colleen D, Potter Larry S, Jou Hann-Chang, Yeung Paul P. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Mov Disord. 2004 Jan;19(1):29–35. [PubMed]
  • Siderowf Andrew, McDermott Michael, Kieburtz Karl, Blindauer Karen, Plumb Sandra, Shoulson Ira. Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial. Mov Disord. 2002 Jul;17(4):758–763. [PubMed]
  • Rovner BW, Folstein MF. Mini-mental state exam in clinical practice. Hosp Pract (Off Ed) 1987 Jan 30;22(1A):99–110. [PubMed]
  • Cummings JL, Donohue JA, Brooks RL. The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease. Am J Geriatr Psychiatry. 2000 Spring;8(2):134–140. [PubMed]
  • Wynn Zakiya J, Cummings Jeffrey L. Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease. Dement Geriatr Cogn Disord. 2004;17(1-2):100–108. [PubMed]
  • McKeith IG, Perry EK, Perry RH. Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology. 1999 Sep 22;53(5):902–905. [PubMed]
  • McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000 Dec 16;356(9247):2031–2036. [PubMed]
  • Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998 Jan;50(1):136–145. [PubMed]
  • Putt Mary E, Ravina Bernard. Randomized, placebo-controlled, parallel group versus crossover study designs for the study of dementia in Parkinson's disease. Control Clin Trials. 2002 Apr;23(2):111–126. [PubMed]
  • Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, Edwards S, Hardyman W, Raftery J, Crome P, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet. 2004 Jun 26;363(9427):2105–2115. [PubMed]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group